| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/08/2006 | EP1622650A2 Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy |
| 02/08/2006 | EP1622637A2 Method and compositions for nerve regeneration |
| 02/08/2006 | EP1622633A2 Treatment of t-cell mediated diseases |
| 02/08/2006 | EP1622630A2 Strontium combinations for the prophylaxis/treatment of cartilage and/or bone conditions |
| 02/08/2006 | EP1622629A2 Controlled release composition containing a strontium salt |
| 02/08/2006 | EP1622628A2 Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol |
| 02/08/2006 | EP1622627A1 Pharmaceutical compositions comprising cereal beta(1-3) beta(1-4) glucan |
| 02/08/2006 | EP1622626A1 Regulation of cell surface proteins |
| 02/08/2006 | EP1622625A1 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.o] non-1 (7)-en-2-yl )alkyl] phosphonic acid and derivatives and methods of use thereof |
| 02/08/2006 | EP1622623A2 Methods of administering estrogens and progestins |
| 02/08/2006 | EP1622622A2 Compound preparation for dizziness |
| 02/08/2006 | EP1622621A2 Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
| 02/08/2006 | EP1622619A2 Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells, or angiogenesis |
| 02/08/2006 | EP1622618A1 Melanocortin receptor-specific compounds |
| 02/08/2006 | EP1622617A2 New pharmaceutical compositions based on anticholinergics and tace-inhibitors |
| 02/08/2006 | EP1622616A2 Inhibitors of akt activity |
| 02/08/2006 | EP1622615A2 Naphthyridine integrase inhibitors |
| 02/08/2006 | EP1622614A2 Use of a topical medicament comprising riluzole |
| 02/08/2006 | EP1622613A2 Compounds, compositions and methods |
| 02/08/2006 | EP1622612A1 Pharmaceutical formulation of the sodium salt of telmisartan |
| 02/08/2006 | EP1622609A2 Methods for treating degenerative diseases/injuries |
| 02/08/2006 | EP1622608A2 Compositions and methods for treating cancer |
| 02/08/2006 | EP1622607A1 Angiotensin ii receptor blockers for preventing the development or progression of microvascular disease due to diabetes |
| 02/08/2006 | EP1622605A1 Use of phthalide derivatives for the treatment and prevention of diabetes mellitus |
| 02/08/2006 | EP1622604A1 Bicalutamide forms, compositions, and processes thereof |
| 02/08/2006 | EP1622603A2 Phenolic acid salts of gabapentin in solid dosage forms and methods of use |
| 02/08/2006 | EP1622602A2 Method for monitoring blood flow and metabolic uptake in tissue with radiolabeled alkanoic acid |
| 02/08/2006 | EP1622601A1 Pharmaceutical compositions |
| 02/08/2006 | EP1622600A1 Pharmaceutical formulation comprising anti-obesity agent and acidulant |
| 02/08/2006 | EP1622599A2 Method of inhibiting atf/creb and cancer cell growth and pharmaceutical compositions for same |
| 02/08/2006 | EP1622598A2 Regulation of guanine nucleotide exchange factor |
| 02/08/2006 | EP1622594A2 Homogeneous, thermoreversible alginate films and soft capsules made therefrom |
| 02/08/2006 | EP1622591A1 Biphasic release of glipizide from monocompartment osmotic dosage form |
| 02/08/2006 | EP1622589A1 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders |
| 02/08/2006 | EP1622588A2 Delivery systems of homogeneous thermoreversible alginate films |
| 02/08/2006 | EP1622586A2 Process for preparing tannate tablet capsule or other solid dosage forms |
| 02/08/2006 | EP1622584A1 Pharmaceutical effervescent formulation comprising amoxycillin and clavulanic acid |
| 02/08/2006 | EP1622579A2 Cosmetic compositions and methods for using same to improve the aesthetic appearance of skin |
| 02/08/2006 | EP1622577A2 Prevention of deficits in neurogenesis with anti-inflammatory agents |
| 02/08/2006 | EP1622573A2 Molecules enhancing dermal delivery of influenza vaccines |
| 02/08/2006 | EP1622569A2 Aza spiro alkane derivatives as inhibitors of metallproteases |
| 02/08/2006 | EP1622567A2 Androgen receptor modulators and methods of use thereof |
| 02/08/2006 | EP1622566A2 Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
| 02/08/2006 | EP1622564A2 Diazabicyclononene derivatives |
| 02/08/2006 | EP1622554A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
| 02/08/2006 | EP1622455A2 Gemini vitamin d3 compounds and methods of use thereof |
| 02/08/2006 | EP1622450A2 Method for promoting uninterrupted sleep by administration of trospium chloride |
| 02/08/2006 | EP1599212A4 Combination therapy for the treatment of immunoinflammatory disorders |
| 02/08/2006 | EP1467762B1 Use of a h1 antagonist and rimexolone as a safe steroid to treat rhinitis |
| 02/08/2006 | EP1455750B1 Viscoelastic ophthalmic compositions comprising hyaluronic acid and chondroitin sulphate |
| 02/08/2006 | EP1453517B1 Platinum derivative pharmaceutical formulations |
| 02/08/2006 | EP1423168B1 Pharmaceutical composition comprising gabapentin or an analogue thereof and an alpha-aminoamide and its analgesic use |
| 02/08/2006 | EP1414463A4 Asymmetric synthesis of kavalactones |
| 02/08/2006 | EP1406865B1 Succinic acid derivatives |
| 02/08/2006 | EP1399138B1 Method for the production of solid formulations of sodium 3-hydroxy-3-methylbutyrate |
| 02/08/2006 | EP1358162B1 Dihydroindole and tetrahydroquinoline derivatives |
| 02/08/2006 | EP1337262A4 Improved ophthalmic and contact lens solutions with a peroxide source and a cationic polymeric preservative |
| 02/08/2006 | EP1331902A4 Improved ophthalmic and contact lens solutions containing forms of vitamin b |
| 02/08/2006 | EP1318978B1 N-acylsulfonamide apoptosis promoters |
| 02/08/2006 | EP1309328A4 Cox-2 inhibitors and the prevention of the side effects of radiation therapy |
| 02/08/2006 | EP1267904A4 Polypeptoid pulmonary surfactants |
| 02/08/2006 | EP1265871B1 Pyridazinyl phenyl hydrazones useful against congestive heart failure |
| 02/08/2006 | EP1257278B1 The use of mirtazapine for the treatment of sleep disorders |
| 02/08/2006 | EP1237904B1 14,15-beta-methylene substituted androgens |
| 02/08/2006 | EP1235776B1 Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 02/08/2006 | EP1187815B1 4-phenyl-pyrimidine derivatives |
| 02/08/2006 | EP1183243B1 Short-acting benzodiazepines |
| 02/08/2006 | EP1156822B1 Iin vitro method for synchronisation of oocyte maturation |
| 02/08/2006 | EP1149082B1 Process for preparing pesticidal intermediates |
| 02/08/2006 | EP1144348B1 Lta 4 hydrolase inhibitors |
| 02/08/2006 | EP1131292B1 Acyclic and cyclic guanidine- and acetamidine derivatives, their preparation and their use as pesticides, esp. as parasiticides |
| 02/08/2006 | EP1119362B1 Use of tetracycline derivatives to enhance interleukin-10 production |
| 02/08/2006 | EP1112362B1 GENE MODIFICATION IN THE GENE FOR THE DIE G$g(b)3-SUB-UNIT OF HUMAN G-PROTEIN |
| 02/08/2006 | EP1109795B1 Thiazoline acid derivatives |
| 02/08/2006 | EP1088104B1 Methods for treating a neurological disease by determining bche genotype |
| 02/08/2006 | EP1039933B1 METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE AND FOR THE PRODUCTION OF $i(IN VITRO) MABS |
| 02/08/2006 | EP1007657B1 Hiv-specific oligonucleotides and methods of their use |
| 02/08/2006 | EP0971587B1 Quinoline leukotriene antagonists |
| 02/08/2006 | EP0969855B1 Novel low density lipoprotein binding proteins and their use in diagnosing and treating atherosclerosis |
| 02/08/2006 | EP0932600B1 Sulfonamide substituted aspartic acid interleukin-1beta converting enzyme inhibitors |
| 02/08/2006 | EP0831869B1 Diphosphonate derivatives of therapeutic agents |
| 02/08/2006 | EP0812318B1 4-aminotetrahydrobenzisoxazole or -isothiazole compounds |
| 02/08/2006 | CN1732251A Method for recovering phytosterol form by-product of vegetable oil refining |
| 02/08/2006 | CN1732172A Epothilone derivatives |
| 02/08/2006 | CN1732171A Pyridopyrrolizine and pyridoindolizine derivatives |
| 02/08/2006 | CN1732165A 1-acyl-pyrrolidine derivatives for the treatment of viral infections |
| 02/08/2006 | CN1732163A Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 02/08/2006 | CN1732162A 1,2,4-triaminobenzenderivater nyttige for behandling AV forstyrrelser i sentralnervesystemet |
| 02/08/2006 | CN1732161A 1,3-diamino-2-hydroxypropane pro-drug derivatives |
| 02/08/2006 | CN1732159A 2-oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors |
| 02/08/2006 | CN1732158A Indazole derivatives as CRF antagonists |
| 02/08/2006 | CN1732153A Novel piperidine derivatives as modulators of chemokine receptor CCR5 |
| 02/08/2006 | CN1732151A 4-nitro-2-[(4'-methoxyl)-phenoxy]-toluenesulfonamide derivant and its medical uses |
| 02/08/2006 | CN1732147A Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| 02/08/2006 | CN1732145A Chiral arylketones in the treatment of neutrophil-dependent inflammatory diseases |
| 02/08/2006 | CN1732016A Modified cytokines for use in cancer therapy |
| 02/08/2006 | CN1732011A Method of treatment for central nervous system injury |
| 02/08/2006 | CN1732010A An agent for controlling Bc1-2 expression comprising ginsenoside F1 as an active component |
| 02/08/2006 | CN1732009A Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes |
| 02/08/2006 | CN1732008A Use of rimexolone in the treatment of dry eye |